Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

Literature DB >> 10961171

Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

S L Allford¹, S J Machin.

Abstract

Entities: Disease

Mesh：

Substances：
von Willebrand Factor

Year: 2000 PMID： 10961171 PMCID： PMC1731230 DOI： 10.1136/jcp.53.7.497

Source DB: PubMed Journal: J Clin Pathol ISSN： 0021-9746 Impact factor: 3.411

× No keyword cloud information.

33 in total

1. Bartonella-like erythrocyte inclusions in thrombotic thrombocytopenic purpura.

Authors: S R Tarantolo; J D Landmark; P C Iwen; A Kessinger; W C Chan; S H Hinrichs
Journal: Lancet Date: 1997-11-29 Impact factor: 79.321

2. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.

Authors: R M van der Plas; M E Schiphorst; E G Huizinga; R J Hené; L F Verdonck; J J Sixma; R Fijnheer
Journal: Blood Date: 1999-06-01 Impact factor: 22.113

3. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.

Authors: T W Chow; N A Turner; M Chintagumpala; P D McPherson; L H Nolasco; L Rice; J D Hellums; J L Moake
Journal: Am J Hematol Date: 1998-04 Impact factor: 10.047

4. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.

Authors: C L Bennett; P D Weinberg; K Rozenberg-Ben-Dror; P R Yarnold; H C Kwaan; D Green
Journal: Ann Intern Med Date: 1998-04-01 Impact factor: 25.391

5. von Willebrand factor mediates increased platelet retention in recurrent thrombotic thrombocytopenic purpura.

Authors: D Karpman; S Lethagen; A Kristoffersson; C Isaksson; L Holmberg
Journal: Thromb Haemost Date: 1997-12 Impact factor: 5.249

6. Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation.

Authors: M T Anthony; Z R Zeigler; J Lister; J M Raymond; R K Shadduck; R E Kramer; J F Gryn; P B Rintels; E C Besa; J N George; B Silver; R Joyce; D Bodensteiner
Journal: Am J Hematol Date: 1998-09 Impact factor: 10.047

7. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors: H M Tsai; E C Lian
Journal: N Engl J Med Date: 1998-11-26 Impact factor: 91.245

8. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors: M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal: N Engl J Med Date: 1998-11-26 Impact factor: 91.245

9. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.

Authors: J L Moake; N A Turner; N A Stathopoulos; L H Nolasco; J D Hellums
Journal: J Clin Invest Date: 1986-12 Impact factor: 14.808

10. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries.

Authors: H Wada; Y Mori; M Shimura; K Hiyoyama; M Ioka; T Nakasaki; M Nishikawa; M Nakano; K Kumeda; T Kaneko; S Nakamura; H Shiku
Journal: Am J Hematol Date: 1998-07 Impact factor: 10.047

4 in total

4. Acute Respiratory Distress Syndrome as an Organ Phenotype of Vascular Microthrombotic Disease: Based on Hemostatic Theory and Endothelial Molecular Pathogenesis.

Authors: Jae C Chang
Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389